Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate

Clinical Cancer Research

Volumn 10, Issue 10, 2004, Pages 3465-3473

  Veltri, Robert W ^a   Khan, Masood A ^a   Miller, M Craig ^b   Epstein, Jonathan I ^a   Mangold, Leslie A ^a   Walsh, Patrick C ^a   Partin, Alan W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CELL NUCLEUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; METASTASIS; MORPHOMETRICS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE EPITHELIUM; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; CELL NUCLEUS; DISEASE PROGRESSION; EPITHELIUM; HUMANS; LINEAR MODELS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; RECURRENCE; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 2542450939     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0635     Document Type: Article

References (33)

1. Carter HB, Partin AW. Diagnosis and staging of prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's Urology. New York: Elsevier Science; 2002. p. 3055-79.
2. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learned and where we are going? J Urol 1999;162:293-306.
3. Walsh PC. Anatomic radical prostatectomy: Evolution of the surgical technique. J Urol 1998;160:2418-24.
4. Stamey TA, Donaldson AN, Yemoto CE, McNeal JE, Sozen S, Gill H. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 1998;160:2412-7.
5. Freedland SJ, Presti JC Jr, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 2003;61:736-41.
6. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999;281:1591-7.
7. Bartels PH, Wied GL. Automated image analysis in clinical pathology. Am J Clin Pathol 1981;75:489-93.
8. Bartels PH. Computer-generated diagnosis and image analysis: an overview. Cancer (Phila.) 1992;69:1636-8.
9. Shankey TV, Kallioniemi OP, Koslowski JM, et al. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 1993;14:497-500.
10. Palcic B. Nuclear texture: can it be used as a surrogate endpoint biomarker? J Cell Biochem (Suppl.) 1994;19:40-6.
11. Boone CW, Lieberman R, Maringer T, Palcic B, Bacus J, Bartels PH. Computer-assisted image analysis-derived intermediate endpoints. Urology 2001;57:129-31.
12. Bacus JW, Grace LJ. Optical microscope system for standardized cell measurements and analyses. Applied Optics 1987;26:3280-93.
13. Diamond DA, Berry SJ, Umbricht C, Jewett HJ, Coffey DS. Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate 1982;3:321-32.
14. Desok K, Charlton JD, Coggins JM, Mohler JL. Semiautomated nuclear shape analysis of prostatic carcinoma and benign prostatic hyperplasia. Analyt Quant Cytol Histol 1994;16:400-14.
15. Veltri RW, Partin AW, Epstein JI, et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and Her-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem (Suppl.) 1994;19:249-58.
16. Veltri RW, Miller MC, Partin AW, Coffey DS, Epstein JI. Ability to predict biochemical progression using Gleason score and computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology 1996;48:685-91.
17. Veltri RW, Partin AW, Miller MC. Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations. J Cell Biochem (Suppl.) 2000;35:151-7.
18. Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW. Prediction of pathological stage in patients with clinical stage Tlc prostate cancer: the new challenge. J Urol 2002;68:100-4.
19. Potter SR, Miller MC, Mangold LA, et al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 1999;54:791-5.
20. Bartels PH, Montironi R, Hamilton PW, Thompson D, Vaught I, Bartels HG. Nuclear chromatin texture in prostatic lesions. I. PIN and adenocarcinoma. Analyt Quant Cytol Histol 1998;20:389-96.
21. Bartels PH, Montironi R, Hamilton PW, Thompson D, Vaught I, Bartels HG. Nuclear chromatin texture in prostatic lesions. II. PIN and malignancy-associated changes. Analyt Quant Cytol Histol 1998;20:397-406.
22. MacAulay C, Lam S, Payne PW, LeRiche JC, Palcic B. Malignancy-associated changes in bronchial epithelial cells in biopsy specimens. Analyt Quant Cytol Histol 1995;17:55-61.
23. Mairinger T, Mikuz G, Gschwendtner A, Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma. Prostate 1999;41:12-9.
24. Beahrs OH, Henson DE, Hutter RVP, editors. American Joint Committee on cancer staging manual. Philadelphia: Lippincott; 1992.
25. Gleason DF, The Veterans Administrative Cooperative Urological Research Group. Histological grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea and Febiger; 1977. p. 171-98.
26. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical prostatectomy: the Johns Hopkins Experience after ten years. Urol Clin N Am 1993;20:713-25.
27. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 2003;62:86-91.
28. Mohler JL, Partin AW, Epstein JI, Lohr WD, Coffey DS. Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections. J Urol 1988;139:1085-90.
29. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol 1989;142:1254-8.
30. Partin AW, Steinberg GD, Pitcock RV, et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer (Phila.) 1992;70:161-8.
31. Epstein JI, Berry SJ, Eggleston JC. Nuclear roundness factor: a predictor of progression in untreated stage A2 prostate cancer. Cancer (Phila.) 1984;54:1666-71.
32. Khan MA, Partin AW. Management of high-risk populations with locally advanced prostate cancer. Oncologist 2003;8:259-69.
33. Veltri RW, Miller MC, An G. Standardization, analytical validation, and quality control of intermediate endpoint biomarkers. Urology 2001;57:164-70.